Beam Therapeutics
BEAM
221 hedge funds and large institutions have $2.32B invested in Beam Therapeutics in 2024 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 80 increasing their positions, 47 reducing their positions, and 18 closing their positions.
206% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 18
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
70% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 47
19% more funds holding
Funds holding: 185 → 221 (+36)
17% more capital invested
Capital invested by funds: $1.99B → $2.32B (+$333M)
3.57% less ownership
Funds ownership: 89.71% → 86.14% (-3.6%)
53% less call options, than puts
Call options by funds: $13.8M | Put options by funds: $29.1M
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$132M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.1M |
| 3 |
Temasek Holdings
Singapore
|
-$39.4M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$37.8M |
| 5 |
State Street
Boston,
Massachusetts
|
-$27.6M |
BEAM Hedge Fund Activity: Q1 2024 in Review
221 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2024, worth a combined $2.32B — up 17% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new BEAM positions and 18 closed out — a net gain of 37 holders — while 80 added to existing stakes and 47 trimmed.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $66M. The largest seller was Morgan Stanley, cutting an estimated $132M.
- 221 institutional investors held Beam Therapeutics (BEAM) as of Q1 2024, up from 185 in Q4 2023.
- Funds reported $2.32B of Beam Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
- 55 funds opened new Beam Therapeutics positions in Q1 2024 and 18 closed out, a net change of +37 holders.
- The largest Beam Therapeutics buyer in Q1 2024 was Darwin Global Management, an estimated $66M added.
- The largest Beam Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $132M sold.
Based on aggregated 13F filings for Q1 2024.